Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | VCP | P55072 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CFTR | P13569 | 2/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180791 | 0.88 | CYP1A1 (0.54) | MAPTPOLBCFTRDGAT1MEN1 | |
| SCHEMBL4939728 | 0.86 | DGAT1 (0.56) | MAPTDGAT1SOAT1MEN1KMT2A | |
| SCHEMBL14617023 | 0.84 | MEN1 (0.61) | MAPTKDM4EDGAT1MEN1KMT2A | |
| SCHEMBL13664061 | 0.84 | MEN1 (0.61) | MAPTKDM4EDGAT1MEN1KMT2A | |
| SCHEMBL180959 | 0.84 | MEN1 (0.61) | MAPTKDM4EDGAT1MEN1KMT2A | |
| SCHEMBL180967 | 0.84 | DGAT1 (0.51) | MAPTKDM4EVCPPOLBCFTR | |
| SCHEMBL4340445 | 0.83 | VCP (0.67) | MAPTKDM4EMAPK1NPSR1VCP | |
| SCHEMBL180802 | 0.82 | DGAT1 (0.54) | DGAT1SOAT1MEN1KMT2A | |
| SCHEMBL4939307 | 0.82 | DGAT1 (0.50) | MAPTNPSR1DGAT1SOAT1MEN1 | |
| SCHEMBL4494798 | 0.82 | ALOX5 (0.57) | DGAT1SOAT1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | claimed |
| US-20130018054-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | claimed |
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-09-20 | — | — | US | claimed |
| EP-2418202-A1 | New compounds | Novartis AG (CH) | 2012-02-15 | — | — | EP | claimed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | claimed |
| US-20090247534-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2009-10-01 | — | — | US | claimed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | claimed |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2008-07-31 | — | — | US | claimed |
| CN-103288721-B | (4-(4-[6-(trifluoromethylpyridin-3-base amino)-containing N heteroaryl]-phenyl)-cyclohexyl)-acetogenin and pharmaceutical use thereof | NOVARTIS AG (CH) | 2016-04-20 | — | — | CN | disclosed |
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912208-B2 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | NOVARTIS AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8835451-B2 | Compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| EP-2418202-B1 | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| EP-2101783-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | Novartis Ag (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| EP-2004607-A2 | NEW COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2008-07-31 | — | — | US | disclosed |
| WO-2008073865-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | MAPT 2141/4885KDM4E 3158/4885MAPK1 222/4885 |
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | MAPT 1739/4885KDM4E 4045/4885MAPK1 3290/4885 |
| US-20090247534-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | MAPT 1739/4885KDM4E 4045/4885MAPK1 3290/4885 |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | MAPT 2157/4885KDM4E 3211/4885MAPK1 227/4885 |
| US-20130018054-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | MAPT 1622/4885KDM4E 4015/4885MAPK1 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.